VPTDF (VentriPoint Diagnostics) Scaled Net Operating Assets: -4.15 (As of Dec. 2025)


VPTDF VentriPoint Diagnostics Ltd VPTDF
6 GF Score
Price $0.08
! 4 Warning Signs
View Full Analysis

What is VentriPoint Diagnostics Scaled Net Operating Assets?

VentriPoint Diagnostics VPTDF 6 Scaled Net Operating Assets is -4.15 as of Dec. 2025. GuruFocus rates VPTDF with a GF Score™ of 6/100. The stock has 4 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

VentriPoint Diagnostics's operating assets for the quarter that ended in Dec. 2025 was $0.30 Mil. VentriPoint Diagnostics's operating liabilities for the quarter that ended in Dec. 2025 was $1.44 Mil. VentriPoint Diagnostics's Total Assets for the quarter that ended in Sep. 2025 was $0.27 Mil. Therefore, VentriPoint Diagnostics's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was -4.15.


VentriPoint Diagnostics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for VentriPoint Diagnostics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VentriPoint Diagnostics Scaled Net Operating Assets Chart

VentriPoint Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.97 -0.02 -0.12 -0.70 -2.45

VentriPoint Diagnostics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.87 -2.65 -2.47 -4.45 -4.15

VPTDF vs ABT, SYK, MDT: Scaled Net Operating Assets Comparison

For the Medical Devices subindustry, VentriPoint Diagnostics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VentriPoint Diagnostics Scaled Net Operating Assets vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where VentriPoint Diagnostics's Scaled Net Operating Assets falls into.


VPTDF
6GF Score
VentriPoint Diagnostics Ltd VPTDF
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VentriPoint Diagnostics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

VentriPoint Diagnostics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(0.302-1.435)/0.462
=-2.45

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.342 - 0.04
=0.302

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=3.327 - 0.083 - 1.809
=1.435

VentriPoint Diagnostics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Sep. 2025 )
=(0.302-1.435)/0.273
=-4.15

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.342 - 0.04
=0.302

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=3.327 - 0.083 - 1.809
=1.435

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -4.15 mean?
VentriPoint Diagnostics (VPTDF) has a Scaled Net Operating Assets of -4.15 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on VentriPoint Diagnostics and its competitors.
Is VentriPoint Diagnostics' Scaled Net Operating Assets too high?
VentriPoint Diagnostics' current Scaled Net Operating Assets is -4.15. Overall, VentriPoint Diagnostics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does VentriPoint Diagnostics' Scaled Net Operating Assets compare to ABT and SYK?
VentriPoint Diagnostics' Scaled Net Operating Assets of -4.15 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on VentriPoint Diagnostics and its competitors. VentriPoint Diagnostics's current Scaled Net Operating Assets is -4.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current Scaled Net Operating Assets of -4.15. The current Scaled Net Operating Assets is -4.15. VentriPoint Diagnostics' overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current Scaled Net Operating Assets is -4.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VentriPoint Diagnostics Business Description

Other Exchanges VPT:Canada
Address 18 Hook Avenue, Unit 101, Toronto, ON, CAN, M6P 1T4
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
6GF Score

Get the complete analysis for VPTDF

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price